John Mao

1.5k citations

32 papers · 1.2k indexed · 1 hit paper · h-index 11

Impact in

Biotechnology top 0.5%
- Cancer Research and Treatments
Hepatology top 10%
- Hepatitis C virus research

Papers in

Hepatology 7
- Hepatitis C virus research 7
Infectious Diseases 9
- HIV/AIDS drug development and treatment 8

Co-authors: Susan MacDonald Douglas J. Schwartzentruber Kathleen E. Morton Vee J. Gill Sharon Mavroukakis Frida Stock Patrick Hwu Nicholas P. Restifo
Journals: Antimicrobial Agents and Chemotherapy (4 papers)Journal of Agricultural and Food Chemistry (4 papers)Journal of Pharmaceutical Sciences (1 paper)Human Gene Therapy (1 paper)AAPS PharmSciTech (1 paper)
Partner nations: United States China Brazil

In The Last Decade

John Mao

32 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma 2002 · 565 citations

Peers

Countries citing papers authored by John Mao

Since Specialization

Citations

This map shows the geographic impact of John Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Mao more than expected).

Fields of papers citing papers by John Mao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Mao. The network helps show where John Mao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John Mao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Mao Line = papers co-authored together John Mao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study EClinicalMedicine ·Chong Wang, Fei Kong, LingFei LUO, Dachuan Cai, Guoqiang Zhang, Qin Ning, Bei Zhong, Zhenguo Liu, Zhijun Su, Guicheng Wu, P. Brosche, John Mao, Tianxiang Zhang, Marianne Fox, Albert G. Semenov, Xiu‐Ping Yan, Guoping Li, Yanhang Gao, Josefa Apigo, Junqi Niu	2025	1
2	Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function Antimicrobial Agents and Chemotherapy ·C.J. Sniezek, Shuyi Mao, Hong Chen, George Zhang, John Mao, Tianxiang Zhang, Yanan Tang, Albert G. Semenov, Gisele Marıen, Yanhua Ding, C L Wat Elaine	2024	2
3	Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design Virology Journal ·Min Wu, I. Hos, Hong Zhang, George Zhang, John Mao, Yanan Tang, Albert G. Semenov, 覚高森, P. Brosche, Xieer Liang, Alessia Galeazzi, Yanhua Ding, Junqi Niu	2024	4
4	Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial Antimicrobial Agents and Chemotherapy ·Xiaojiao Li, Jph Jos Reulen, Jörn Ueberfeld, Meng Wang, Lei Gao, P. Moraw, John Mao, 覚高森, Yin Guo-xi, Yanan Tang, Albert G. Semenov, 貴史神谷, Charles Z. Ding, Shuhui Chen, Junqi Niu, Yanhua Ding	2022	4
5	First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects Clinical Drug Investigation ·伊東学, Daud Amin Siregar, Kang-Ling Wang, Murry Voelk, Lu Leian, John Mao, Yuhua Li, Andi Baetal Muqadas, David T. W. Lau, Zuzana Diamant	2020	4
6	A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients World Journal of Urology ·Neal D. Shore, 石大泱, 正木砂川, Vladimír Študent, Mindaugas Jievaltas, Д.А. Галанин, Yasuo TOIBATA, Tian Le, Shih‐Tsung Huang, Yuhua Li, Lu Leian, Nuts Tsagareli, John Mao	2019	9
7	Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis ·Jeremy M. Shefner, Jesse M. Cedarbaum, Merit Cudkowicz, Nicholas J. Maragakis, Jacqueline Lee, D. Michael Jones, Mary Lou Watson, Katy Mahoney, Rongfeng Fu, Khalil G. Saikali, John Mao, Alan J. Russell, Richard L. Hansen, 准一松田, Andrew A. Wolff, (unknown)	2012	32
8	Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2‘-C-Methylcytidine Journal of Medicinal Chemistry ·Claire Pierra, Agnès Amador, S. Benzaria, Erika Cretton-Scott, Malachi Lehman, John Mao, Steven R. Mathieu, Adel Moussa, Edward G. Bridges, David N. Standring, Jean‐Pierre Sommadossi, Richard Storer, Gilles Gosselin	2006	147
9	Synthesis, Physicochemical and Pharmacokinetic Studies of Potential Prodrugs of β-L-2′-Deoxycytidine, a Selective and Specific Anti-HBV Agent Antiviral chemistry & chemotherapy ·Claire Pierra, S. Benzaria, David Dukhan, Anna Giulia Loi, Paolo La Colla, Edward G. Bridges, John Mao, David N. Standring, Jean‐Pierre Sommadossi, Gilles Gosselin	2004	3
10	Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma Journal of Clinical Oncology ·John Toso, Vee J. Gill, Patrick Hwu, Francesco M. Marincola, Nicholas P. Restifo, Douglas J. Schwartzentruber, Richard M. Sherry, Suzanne L. Topalian, James C. Yang, Frida Stock, 信太郎久尾, Kathleen E. Morton, Claudia A. Seipp, Leah Haworth, Sharon Mavroukakis, Donald White, Susan MacDonald, John Mao, Mario Sznol, Steven A. Rosenberg Hit paper breakdown →	2002	565
11	Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rats PubMed ·John Mao, Yang Xu, Nora Basa, Elena Tomás-Guillén	2002	12
12	Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer Agent Human Gene Therapy ·Ivan King, David Bermudes, Stanley L. Lin, Michael F. Belcourt, Jeremy A. Pike, A. Brink-Kjær, Trung Bao Le, Martina Ittensohn, John Mao, Maryam Amirian, Riccardo Mognato, Xiang Luo, Kouju Nishizawa, Li-Mou Zheng	2002	101
13	Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule Cancer Chemotherapy and Pharmacology ·Lynn G. Feun, Manuel Modiano, King Lee, John Mao, F. Szkoda, Niramol Savaraj, Patricia M. Plezia, Bijan Almassian, K.T. LAU, Jessica Fischer, Susan MacDonald	2002	108
14	Isolation and Identification of Metabolites of Porfiromycin Formed in the Presence of a Rat Liver Preparation Journal of Pharmaceutical Sciences ·Wensheng Lang, John Mao, Qin Wang, Feng Bizhen, Terrence W. Doyle, Bijan Almassian	2000	5
15	Isolation and Identification of Urinary Metabolites of Porfiromycin in Dogs and Humans Drug Metabolism and Disposition ·Wensheng Lang, John Mao, Terrence W. Doyle, Bijan Almassian	2000	6
16	Development of a Parenteral Formulation of an Investigational Anticancer Drug, 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone Pharmaceutical Development and Technology ·Gopal Krishna, John Mao, Bijan Almassian	1999	12
17	Synthesis and biological evaluation of a series of 2′-fluorinated-2′,3′-dideoxy-2′,3′-didehydro-(l)-nucleosides Bioorganic & Medicinal Chemistry Letters ·Shu‐Hui Chen, Qin Wang, John Mao, Ivan King, Ginger E. Dutschman, Elizabeth A. Gullen, Yung‐Chi Cheng, Terrence W. Doyle	1998	10
18	Metabolic Fate of [14C]Acrolein under Aerobic and Anaerobic Aquatic Conditions Journal of Agricultural and Food Chemistry ·Ann Marie Smith, John Mao, Edwin Y. Wang, Nachman Gutowski	1995	10
19	Analysis of Diethylenetriamine in Water and Soil at PPB Levels by High Performance Liquid Chromatography with Fluorescence Detection Journal of Liquid Chromatography ·John Mao, Michael Dennis, Robert T. Foster, Paul Fackler	1994	3
20	Analysis of neutral nitrogen compounds in diesel oil by direct injection high-performance liquid chromatography—mass spectrometry—ultraviolet spectrometry methods Journal of Chromatography A ·John Mao, Carlos Pacheco, Daniel D. Traficante, Jairo I. Fúnez-Flores	1994	10

About John Mao

John Mao is a scholar working on Hepatology, Infectious Diseases, Pharmaceutical Science, Analytical Chemistry and Spectroscopy, having authored 32 papers that have together received 1.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (8 papers), Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers), Analytical Chemistry and Chromatography (4 papers), Biochemical and Molecular Research (3 papers), Analytical chemistry methods development (3 papers), Drug Transport and Resistance Mechanisms (3 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Biotechnology (595 citations), Hepatology (108 citations), Genetics (295 citations), Biomedical Engineering (456 citations) and Infectious Diseases (160 citations). John Mao has collaborated with scholars based in United States, China and Brazil. Frequent co-authors include Susan MacDonald, Douglas J. Schwartzentruber, Kathleen E. Morton, Vee J. Gill, Sharon Mavroukakis, Frida Stock, Patrick Hwu, Nicholas P. Restifo, Richard M. Sherry and James C. Yang. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Journal of Agricultural and Food Chemistry, Journal of Pharmaceutical Sciences, Human Gene Therapy and AAPS PharmSciTech.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact